HSCT for Fanconi anemia in children: factors that influence early and late results - PubMed (original) (raw)
Review
. 2008 Oct:42 Suppl 2:S51-3.
doi: 10.1038/bmt.2008.284.
Affiliations
- PMID: 18978745
- DOI: 10.1038/bmt.2008.284
Review
HSCT for Fanconi anemia in children: factors that influence early and late results
J-H Dalle. Bone Marrow Transplant. 2008 Oct.
Abstract
Fanconi anemia (FA) is a rare autosomal recessive disease characterized by congenital abnormalities, cancer predisposition and progressive BM failure. FA patients present spontaneous and induced chromosome breakage. Hematopoietic SCT (HSCT) represents the unique therapeutic option to restore normal hematopoiesis when marrow failure or clonal hematopoietic abnormality occurs. Conventional myeloablative conditioning regimen, especially including a high dose of irradiation, appeared strongly toxic for FA patients. Then, reduced-intensity conditioning regimens were developed successfully for those patients. However, TRM still remained higher than for other HSCT indications. The development of fludarabine containing a non-myeloablative conditioning regimen appears to be a major progress. Long-term follow-up is absolutely necessary.
Similar articles
- Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation.
Masserot C, Peffault de Latour R, Rocha V, Leblanc T, Rigolet A, Pascal F, Janin A, Soulier J, Gluckman E, Socié G. Masserot C, et al. Cancer. 2008 Dec 15;113(12):3315-22. doi: 10.1002/cncr.23954. Cancer. 2008. PMID: 18831513 - The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group.
Locatelli F, Zecca M, Pession A, Morreale G, Longoni D, Di Bartolomeo P, Porta F, Fagioli F, Nobili B, Bernardo ME, Messina C; Italian pediatric group. Locatelli F, et al. Haematologica. 2007 Oct;92(10):1381-8. doi: 10.3324/haematol.11436. Haematologica. 2007. PMID: 18024375 - Allogeneic hematopoietic stem cell transplantation of patients with FA and high risk features using fludarabine without radiation.
Baker JM, Lewis VA, Fernandez CV, Duval M, Crooks BN, Yuille K, Freedman MH, Doyle JJ, Dror Y. Baker JM, et al. Pediatr Blood Cancer. 2009 May;52(5):683-5. doi: 10.1002/pbc.21921. Pediatr Blood Cancer. 2009. PMID: 19156855 Clinical Trial. - Fanconi Anemia: Overview of the Disease and the Role of Hematopoietic Transplantation.
Schifferli A, Kühne T. Schifferli A, et al. J Pediatr Hematol Oncol. 2015 Jul;37(5):335-43. doi: 10.1097/MPH.0000000000000374. J Pediatr Hematol Oncol. 2015. PMID: 26086276 Review. - [Fanconi anemia in 2012: diagnosis, pediatric follow-up and treatment].
Lanneaux J, Poidvin A, Soole F, Leclerc G, Grimaud M, Dalle JH. Lanneaux J, et al. Arch Pediatr. 2012 Oct;19(10):1100-9. doi: 10.1016/j.arcped.2012.07.023. Epub 2012 Sep 7. Arch Pediatr. 2012. PMID: 22959745 Review. French.
Cited by
- Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity.
Wu L, Amarachintha S, Xu J, Oley F Jr, Du W. Wu L, et al. Br J Haematol. 2018 Nov;183(3):445-456. doi: 10.1111/bjh.15548. Epub 2018 Aug 14. Br J Haematol. 2018. PMID: 30106181 Free PMC article. - Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin.
Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes DB, Tate TA, Czechowicz A, Kfoury Y, Ruchika F, Rossi DJ, Verdine GL, Mansour MK, Scadden DT. Palchaudhuri R, et al. Nat Biotechnol. 2016 Jul;34(7):738-45. doi: 10.1038/nbt.3584. Epub 2016 Jun 6. Nat Biotechnol. 2016. PMID: 27272386 Free PMC article. - Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease.
Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Hawryluk EB, Murphy GF, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MR. Hanash AM, et al. Immunity. 2012 Aug 24;37(2):339-50. doi: 10.1016/j.immuni.2012.05.028. Immunity. 2012. PMID: 22921121 Free PMC article. - Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen.
Shimada A, Takahashi Y, Muramatsu H, Hama A, Ismael O, Narita A, Sakaguchi H, Doisaki S, Nishio N, Tanaka M, Yoshida N, Matsumoto K, Kato K, Watanabe N, Kojima S. Shimada A, et al. Int J Hematol. 2012 Jun;95(6):675-9. doi: 10.1007/s12185-012-1079-9. Epub 2012 Apr 22. Int J Hematol. 2012. PMID: 22527854 - Formation of cyclophosphamide specific DNA adducts in hematological diseases.
Johnson LA, Malayappan B, Tretyakova N, Campbell C, MacMillan ML, Wagner JE, Jacobson PA. Johnson LA, et al. Pediatr Blood Cancer. 2012 May;58(5):708-14. doi: 10.1002/pbc.23254. Epub 2011 Jul 25. Pediatr Blood Cancer. 2012. PMID: 21793181 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources